Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Cardiac disease

Cardiac disease

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cardiac disease

17 trials tracked for Cardiac disease: 5 in phase 3 or 4 and 1 with published results. The most-cited published study has 59 citations.

17Trials tracked
5Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 4 Phase 2 3 Other / NA 9
  1. Phase 3 Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease Completed · 59 cited
  2. Phase 4 Platelet Transfusion During Neonatal Open Heart Surgery Completed
  3. Phase 3 DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY Completed
  4. Phase 3 DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY Completed
  5. Phase 3 Hemodynamic Effect of Norepinephrine Versus Vasopressin on the Pulmonary Circulation in Cardiac Surgery Patients: Completed
  6. Phase 2 A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography Completed
Show 11 more trials
  1. Phase 2 Low Dose Continuous Furosemide Effect on Cardiac Surgery Patients With Kidney Dysfunction Completed
  2. Phase 2 Lidocaine as an Endotracheal Tube (ETT) Cuff Media Completed
  3. N/A Clinical Investigation for Safety and Efficacy Study of CELT ACD (Arterial ClosureDevice) Completed
  4. N/A Intensive Alveolar Recruitment Protocol After Cardiac Surgery Completed
  5. N/A A Study of Physical Activity paTTerns and Major Health Events in Older People With Implantable Cardiac Devices Completed
  6. N/A A Culturally-Based Palliative Care Tele-consult Program for Rural Southern Elders Completed
  7. N/A Atrial Natriuretic Peptide in Assessing Fluid Status Completed
  8. N/A Retrospective Experience Of CIED Implantation Completed
  9. N/A PROSPECTIVE EVALUATION OF HEARTFOCUS Completed
  10. N/A Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk Completed
  11. N/A PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Cardiac disease: what the trials found

Established evidence regarding cardiac imaging and hemodynamics shows that the DEFINITY ultrasound contrast agent demonstrated no significant difference in LVEF percentage differences from CMR by blinded readers [5, 6]. Additionally, for sub-optimal echocardiograms, there was no statistically significant difference in LVEF accuracy when using DEFINITY 6.

In hemodynamic monitoring and management, vasopressin showed no significant difference in mPAP-to-MAP ratio 4 or RV free wall strain 4. Platelet transfusion was associated with specific inotrope scores (5.6 to 7.1) and zero mortality at 30 days in a pediatric cohort 2. Edoxaban was also evaluated as an established intervention 3.

Recent results — preliminary, needs further review

  • * Glucagon-like peptide 1 receptor agonist is currently being investigated 10.

For the clinician treating this condition

  • DEFINITY contrast agents provide consistent LVEF measurements comparable to CMR in both standard and sub-optimal echocardiograms [5, 6].
  • Vasopressin does not significantly alter mPAP-to-MAP ratios or RV free wall strain 4.
  • Platelet transfusion is associated with specific inotrope scores in pediatric populations with no reported mortality at 30 days 2.

AI synthesis of 5 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Risk factors for multidrug-resistant organism infections in neutropenic patients
Infectious Disease Cohort
Risk factors for multidrug-resistant organism infections in neutropenic patients Doctors Can Now Predict Deadly Infections in Chemo Patients Before They Strike
This observational cohort study in 391 neutropenic patients identified risk factors for multidrug-resistant organism infections.
This new prediction model could help doctors protect vulnerable patients from life-threatening infections that resist standard treatment.
Frontiers Apr 23, 2026
Technology-based Cardiac rehabilitation Therapy improves functional capacity and quality of life in women with cardiac disease
Physical Medicine & Rehab RCT
Technology-based Cardiac rehabilitation Therapy improves functional capacity and quality of life in women with cardiac disease New Tech-Based Program Helps Women With Heart Disease Get Stronger—Without Leaving Home
This randomized controlled trial evaluated Technology-based Cardiac rehabilitation Therapy (TaCT) versus standard care in n=89 women with st…
This study shows that a tailored, tech-based cardiac rehab program can help women with heart disease improve their physical health and quali…
Apr 22, 2026